Innovative Medtech(IMTH)
$0.000.00 (0.00%)
IMTH
Innovative Medtech financials statements
$0.00
At close:0.00 (0.00%)
Innovative Medtech (IMTH) Ratios
5 Followers
Innovative Medtech Ratios
IMTH's free cash flow for Q4 2025 was $2.95M. For the 2025 fiscal year, IMTH's free cash flow was increased by $0.00 and operating cash flow was $2.95M. See a summary of the company’s cash flow.
| Ratios | Jun 25 | Jun 24 | Jun 23 | Jun 22 | Jun 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.02 | 0.07 | 0.11 | 0.13 | 0.24 |
| Quick Ratio | 0.02 | 0.07 | 0.11 | 0.14 | 0.24 |
| Cash Ratio | 0.01 | 0.03 | 0.04 | 0.08 | 0.16 |
| Solvency Ratio | 0.99 | -1.28 | -0.62 | -2.90 | -0.61 |
| Operating Cash Flow Ratio | 2.36 | -0.04 | -0.05 | -0.15 | 0.01 |
| Short-Term Operating Cash Flow Coverage | 4.74 | -0.12 | -0.13 | -0.47 | 0.03 |
| Net Current Asset Value | $ -1.28M | $ -5.85M | $ -5.36M | $ -5.70M | $ -4.64M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 2.59 | 3.37 | 0.49 | 0.49 | 0.43 |
| Debt-to-Equity Ratio | -0.62 | -0.40 | -1.67 | -1.66 | -40.38 |
| Debt-to-Capital Ratio | -1.61 | -0.67 | 2.50 | 2.51 | 1.03 |
| Long-Term Debt-to-Capital Ratio | 0.00 | -0.08 | -0.39 | -0.30 | 1.15 |
| Financial Leverage Ratio | -0.24 | -0.12 | -3.40 | -3.40 | -94.58 |
| Debt Service Coverage Ratio | -3.39 | -4.53 | -2.24 | -12.44 | -2.51 |
| Interest Coverage Ratio | 50.25 | -21.47 | -16.34 | -95.36 | -4.12 |
| Debt to Market Cap | 0.24 | 0.17 | 0.14 | 0.03 | 0.14 |
| Interest Debt Per Share | 0.01 | 0.10 | 0.11 | 0.15 | 0.31 |
| Net Debt to EBITDA | -0.32 | -0.27 | -0.60 | -0.11 | -0.59 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 96.38% | 96.70% | 94.61% | 97.24% |
| EBIT Margin | 0.00% | -424.11% | -198.61% | -1376.50% | -885.88% |
| EBITDA Margin | 0.00% | -420.71% | -195.30% | -1371.11% | -883.02% |
| Operating Profit Margin | 0.00% | -234.19% | -210.09% | -1406.63% | -203.07% |
| Pretax Profit Margin | 0.00% | -435.01% | -211.48% | -1391.22% | -935.15% |
| Net Profit Margin | 0.00% | -435.01% | -211.48% | -1391.22% | -935.15% |
| Continuous Operations Profit Margin | 0.00% | -435.01% | -211.48% | -1391.22% | -935.15% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | -46.50% | 185.75% | 100.66% | 98.90% | 460.51% |
| Return on Assets (ROA) | 506.73% | -1217.86% | -81.99% | -376.20% | -62.26% |
| Return on Equity (ROE) | -120.50% | 144.79% | 278.82% | 1280.31% | 5888.72% |
| Return on Capital Employed (ROCE) | 259.15% | 123.65% | -414.71% | -1926.73% | -28.92% |
| Return on Invested Capital (ROIC) | 675.78% | 238.90% | -152.86% | -756.12% | -19.36% |
| Return on Tangible Assets | 506.73% | -1217.86% | -323.28% | -1233.02% | -184.40% |
| Earnings Yield | 47.74% | -73.93% | -31.35% | -31.16% | -30.73% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 10.72 | 7.37 | 6.08 | 1.53 |
| Payables Turnover | 0.00 | 0.05 | 0.05 | 0.05 | 0.01 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | -2.57 | 0.00 |
| Fixed Asset Turnover | 0.00 | 5.07 | 2.37 | 1.38 | 0.32 |
| Asset Turnover | 0.00 | 2.80 | 0.39 | 0.27 | 0.07 |
| Working Capital Turnover Ratio | 0.00 | -0.52 | -0.53 | -0.47 | -0.11 |
| Cash Conversion Cycle | 0.00 | -7249.82 | -6943.76 | -7987.87 | -26202.32 |
| Days of Sales Outstanding | 0.00 | 34.06 | 49.50 | 60.06 | 237.88 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | -142.24 | 0.00 |
| Days of Payables Outstanding | 0.00 | 7283.88 | 6993.25 | 7905.68 | 26440.19 |
| Operating Cycle | 0.00 | 34.06 | 49.50 | -82.18 | 237.88 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.08 | -0.01 | -0.01 | -0.04 | 0.00 |
| Free Cash Flow Per Share | 0.08 | -0.01 | -0.01 | -0.04 | 0.00 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -3.61 | -13.42 | -12.57 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | -3.61 | -13.42 | -12.57 | 0.00 |
| Operating Cash Flow Coverage Ratio | 4.74 | -0.08 | -0.08 | -0.25 | 0.01 |
| Operating Cash Flow to Sales Ratio | 0.00 | -0.10 | -0.10 | -0.45 | 0.08 |
| Free Cash Flow Yield | 115.87% | -2.18% | -1.56% | -1.09% | 0.26% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 2.17 | -1.35 | -3.19 | -3.21 | -3.25 |
| Price-to-Sales (P/S) Ratio | 0.00 | 5.88 | 6.75 | 44.64 | 30.43 |
| Price-to-Book (P/B) Ratio | -2.52 | -1.96 | -8.89 | -41.09 | -191.60 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 0.86 | -45.93 | -64.09 | -92.09 | 378.06 |
| Price-to-Operating Cash Flow Ratio | 0.86 | -58.64 | -68.87 | -99.42 | 378.06 |
| Price-to-Earnings Growth (PEG) Ratio | -0.02 | -0.01 | 0.04 | -0.02 | 0.04 |
| Enterprise Value Multiple | -1.63 | -1.67 | -4.05 | -3.37 | -4.03 |
| Enterprise Value | 3.29M | 12.82M | 13.66M | 59.99M | 12.43M |
| EV to EBITDA | -1.63 | -1.67 | -4.05 | -3.37 | -4.03 |
| EV to Sales | 0.00 | 7.02 | 7.92 | 46.22 | 35.60 |
| EV to Free Cash Flow | 1.07 | -54.83 | -75.22 | -95.34 | 442.32 |
| EV to Operating Cash Flow | 1.07 | -70.00 | -80.83 | -102.92 | 442.32 |
| Tangible Book Value Per Share | -0.03 | -0.23 | -0.22 | -0.29 | -0.45 |
| Shareholders’ Equity Per Share | -0.03 | -0.23 | -0.06 | -0.08 | -0.01 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.08 | 0.08 | 0.08 | 0.04 |
| Net Income Per Share | 0.03 | -0.33 | -0.17 | -1.09 | -0.41 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | -0.62 | 1.03 | 1.06 | 1.01 | 1.06 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 3.34 | 1.36 | 15.07 | 3.03 |
| Stock-Based Compensation to Revenue | 0.00 | 0.95 | 0.00 | 12.87 | 0.00 |
| Income Quality | 2.43 | 0.02 | 0.05 | 0.03 | -0.01 |
Currency in USD
